MoneyWorks4Me

Zydus Lifesciences - Quaterly Results

07 Nov 2023 Evaluate
Revenue showed a marginal decline at Rs. 21593.00 millions. For the quarter ended September 2023, as compared to corresponding quarter of last year.Profit for the quarter ended September 2023 rises by 78.45% to Rs. 8050.00  millions from Rs. 4511.00 millions.Operating Profit saw a handsome growth to 11839.00 millions from 7882.00 millions in the quarter ended September 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 21593.00 22618.00 -4.53 51150.00 41393.00 23.57 87316.00 78369.00 11.42
Other Income 6212.00 2462.00 152.32 7036.00 4013.00 75.33 5484.00 1787.00 206.88
PBIDT 11839.00 7882.00 50.20 24073.00 13842.00 73.91 30028.00 20968.00 43.21
Interest 909.00 641.00 41.81 1806.00 1047.00 72.49 2782.00 1349.00 106.23
PBDT 10930.00 7241.00 50.95 22267.00 12795.00 74.03 25208.00 16426.00 53.46
Depreciation 1249.00 1240.00 0.73 2461.00 2471.00 -0.40 4886.00 4787.00 2.07
PBT 9681.00 6001.00 61.32 19806.00 10324.00 91.84 20322.00 11639.00 74.60
TAX 1631.00 1490.00 9.46 3947.00 2498.00 58.01 5030.00 3060.00 64.38
Deferred Tax -85.00 44.00 -293.18 -133.00 38.00 -450.00 412.00 458.00 -10.04
PAT 8050.00 4511.00 78.45 15859.00 7826.00 102.65 15292.00 8579.00 78.25
Equity 1012.00 1012.00 0.00 1012.00 1024.00 -1.17 1012.00 1024.00 -1.17
PBIDTM(%) 54.83 34.85 57.33 47.06 33.44 40.74 34.39 26.76 28.53
Peers
Company Name CMP
Sun Pharma. Inds. 1745.00
Dr. Reddys Labs. 1242.00
Cipla 1331.00
Lupin 1953.75
Zydus Lifesciences 1113.00
View more..